Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 9Lung Neoplasms 5Myeloproliferative Disorders 4Leukemia, Myelomonocytic, Chronic 4Sarcoma 3Prostatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomatitis 2Primary Myelofibrosis 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Prostate Cancer Metastatic 1Polycythemia Vera 1

Interventions

Azacitidine 2midostaurin 1Vorinostat 1Nivolumab 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × GATA2 Deficiency × Injections × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡